Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Wei Yen Chan(Melanoma Institute Australia), Helen Rizos(Macquarie University), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(The University of Sydney), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Jenny Lee(Blacktown & Mount Druitt Hospital), Maria Gonzalez(The University of Sydney), Alexander M. Menzies(The University of Sydney)
Cited by 22
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k